[{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Altasciences Company Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altasciences Company Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altasciences Company Inc \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alladapt Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"ADP101","moa":"Envelope (E) protein","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Altasciences Company Inc \/ Alladapt Immunotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Altasciences Company Inc \/ Alladapt Immunotherapeutics"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Palisade Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AZD4041","moa":"Orexin receptor type 1 (HCRTR1)","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Altavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alzamend Neuro","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase II","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alzamend Neuro","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase II","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Xortx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"10","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Metsera","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MET-097i","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alzamend Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Neurology","graph2":"Phase III","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Alzamend Neuro","highestDevelopmentStatusID":"10","companyTruncated":"Altasciences Company Inc \/ Alzamend Neuro"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Spyre Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPY002-091","moa":"TL1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VK4-116","moa":"D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"Tetra BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Kratom","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Spyre Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SPY001-001","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Spyre Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SPY002-072","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Spyre Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SPY003-207","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Algorithme Pharma Inc.","sponsor":"Algorithme Pharma Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ademetionine","moa":"Methionine metabolism","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Algorithme Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Algorithme Pharma Inc. \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quaternary Ammonium Palmitoyl Glycol Chitosan","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altasciences Company Inc \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Altasciences Company Inc \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Film","sponsorNew":"Altasciences Company Inc \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Altasciences Company Inc \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"HT-TBI","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"4","companyTruncated":"Altasciences Company Inc \/ Altasciences Company Inc"}]
Find Clinical Drug Pipeline Developments & Deals by Altasciences Company Inc
Details :
AnQlar (quaternary ammonium palmitoyl glycol chitosan) is a nanoparticle intended to prevent the spread of negatively charged viruse such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at no...
Product Name : AnQlar
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) :
Quaternary Ammonium Palmitoyl Glycol Chitosan
Reset All
